STAT

Opinion: The emergence of laboratory benefits managers: PBM déjà vu?

If left to develop unmonitored, as happened with PBMs, laboratory benefits managers could worsen rather than ease issues related to health care costs and utilization without improving outcomes.

Pharmacy benefits managers (PBMs), the companies that administer prescription drug coverage for employers, municipalities, insurance companies, and the like, have taken heat for adding to the cost of drugs instead of controlling or lowering them. Sen. Ron Wyden (D-Ore.) has called PBMs “gnarled, confounding riddles.” An emerging parallel industry, laboratory benefits managers (LBMs), could be following in their footsteps.

Although the exact scope of work varies from contract to contract, the tendrils of laboratory benefits managers can extend from routine lab tests, such as cholesterol or HbA1c, to genetic tests, such as proprietary diagnostic tests for cancer, and even to digital diagnostics such as home blood pressure monitoring. In some cases, they may also manage MRIs or other forms of imaging

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

Related Books & Audiobooks